SRR934798
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 127.6281208935611
- age_years
- 37
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.405
- UV_RESPONSE_DN+0.354
- OXIDATIVE_PHOSPHORYLATION+0.282
- MTORC1_SIGNALING+0.278
- NOTCH_SIGNALING+0.271
- ANDROGEN_RESPONSE+0.270
- TGF_BETA_SIGNALING+0.265
- MITOTIC_SPINDLE+0.261
- HEDGEHOG_SIGNALING+0.241
- MYC_TARGETS_V1+0.230
Top 10 suppressed
- COAGULATION-0.342
- ALLOGRAFT_REJECTION-0.314
- INTERFERON_ALPHA_RESPONSE-0.281
- APICAL_SURFACE-0.279
- IL6_JAK_STAT3_SIGNALING-0.263
- INTERFERON_GAMMA_RESPONSE-0.248
- KRAS_SIGNALING_DN-0.244
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.240
- INFLAMMATORY_RESPONSE-0.231
- TNFA_SIGNALING_VIA_NFKB-0.230
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BAA2D0D4-DD8C-4F80-8D37-986AFC578536 | — | — | 0.881 |
| 2 | 9E2420C3-FD2A-45BB-B5A3-DC25D9F7CB3C | — | — | 0.881 |
| 3 | EF7D394C-BAB6-4826-AE09-9E5E884E0023 | — | — | 0.868 |
| 4 | DE406E2B-39AF-4A24-B2BE-0F7CDCBE9D85 | — | — | 0.849 |
| 5 | D47BE4CF-FF4F-4422-89AE-9AFAE192309C | — | — | 0.839 |
| 6 | 713B4DA5-FA8A-4E52-BACF-19B912467FBB | — | — | 0.833 |
| 7 | SJEPD031010_D1.RNA-Seq | EPN | EPN Tumor | 0.821 |
| 8 | BB79CABB-0912-4E02-ACD9-82EF3AB8B598 | — | — | 0.818 |
| 9 | MNG730 | — | — | 0.815 |
| 10 | E3818BAA-BA28-4CE4-A745-BB3692883888 | — | — | 0.809 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.405 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.354 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.282 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.278 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.271 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.270 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.265 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.261 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.241 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.230 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.215 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.146 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.131 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.121 | Cobimetinib | — uncovered |
| ADIPOGENESIS | 0.113 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.087 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.058 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.052 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.038 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.025 | Inavolisib | — uncovered |